News & Publications
Highlights the specific binding site and unique mechanism by which Gate’s NMDAR modulators directly enhance NMDA function in the mPFC, resulting in NMDA-mediated plasticity and rapid and sustained antidepressant activity. Also highlights the differing mechanistic actions of ketamine, and how Gate’s NMDAR modulators represent a more well-tolerated downstream approach compared to ketamine, while maintaining potent, rapid, and sustained antidepressant effects.
Highlights the molecular, cellular, and behavioral actions of Gate’s class of molecules to further characterize the mechanisms underlying their antidepressant actions and differentiates those mechanisms from NMDAR antagonists.
Highlights the original Phase 2 proof-of-concept depression study with the first generation molecule in our class of NMDAR modulators. GLYX-13 reduced depressive symptoms within 2 hours of administration and the effect was maintained for 7 days on average, and the molecule did not elicit psychotomimetic or other significant side effects.
Highlights the original discovery that our class of NMDA receptor modulators have pharmacology that exhibits efficacy in non-clinical models of depression.